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Abstract
Background: Group B Streptococcus (GBS) is a leading cause of morbidity and mortality in infants in both
developed and developing countries. To our knowledge, only a few studies have been reported the clinical
features, treatment and outcomes of the GBS disease in China. The severity of neonatal GBS disease in China
remains unclear. Population-based surveillance in China is therefore required.
Methods: We retrospectively collected data of <3 months old infants with culture-positive GBS in sterile samples
from three large urban tertiary hospitals in South China from Jan 2011 to Dec 2014. The GBS isolates and their
antibiotic susceptibility were routinely identified in clinical laboratories in participating hospitals. Serotyping and
multi-locus sequence typing (MLST) were also conducted for further analysis of the neonatal GBS disease.
Results: Total 70 cases of culture-confirmed invasive GBS infection were identified from 127,206 live births born in
studying hospitals, giving an overall incidence of 0.55 per 1000 live births (95% confidence interval [CI] 0.44–0.69).
They consisted of 49 with early-onset disease (EOD, 0.39 per 1000 live births (95% CI 0.29–0.51)) and 21 with
late-onset disease (LOD, 0.17 per 1000 live births (95% CI 0.11–0.25)). The incidence of EOD increased significantly over
the studying period. Five infants (4 EOD and 1 LOD) died before discharge giving a mortality rate of 7.1% and five
infants (7.1%, 2 EOD and 3 LOD) had neurological sequelae. Within 68 GBS isolates from GBS cases who born in the
studying hospitals or elsewhere, serotype III accounted for 77.9%, followed by Ib (14.7%), V (4.4%), and Ia (2.9%). MLST
analysis revealed the presence of 13 different sequence types among the 68 GBS isolates and ST-17 was the most
frequent sequence type (63.2%). All isolates were susceptible to penicillin, ceftriaxone, vancomycin and linezolid, while
57.4% and 51.5% were resistant to erythromycin and clindamycin, respectively.
Conclusions: This study gains the insight into the spectrum of GBS infection in south China which will facilitate the
development of the guidance for reasonable antibiotics usage and will provide evidence for the implementation of
potential GBS vaccines in the future.
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Background
Group B Streptococcus (GBS) is recognized as a leading
cause of neonatal morbidity and mortality around the
world [1–4]. The incidence varies significantly by region.
A systematic review and meta-analysis reported an esti-
mated global incidence of GBS in infants <3 months old
of 0.53 per 1000 live births (95% confidence interval [CI]
0.44–0.62) [5]. The incidence was highest in Africa, with
1.21 per 1000 live births, followed by the Americas (0.67
per 1000 live births) and Europe (0.57 per 1000 live
births) [5]. Southeast Asia had the lowest incidence, at
0.02 per 1000 live births [5]. However, data from Asia
are very limited and the disease burden in Mainland
China remains unclear [5, 6].
The Center for Disease Control and Prevention (CDC)
in US has issued a perinatal disease prevention strategy
in 1996 with two revisions in 2002 and 2010 suggesting
universal culture-based screening of pregnant women
and intrapartum antibiotic prophylaxis (IAP) for GBS
colonized women as an approach for neonatal GBS pre-
vention. The implementation of the guidelines decreased
the incidence of early-onset GBS disease (EOD; occur-
ring in infants <7 days old) from 1.7 per 1000 live births
in 1993 to 0.25 per 1000 live births by 2014 [7–9]. Spe-
cific guidelines such as IAP for GBS prevention are lack-
ing in China and only few hospitals strictly follow the
guideline issued by the US CDC. The three study hospi-
tals did not implement IAP during the studying period.
Our previous study, the first prospective observational
study conducted in Mainland China, showed an incidence
of GBS of 0.28 per 1000 live births (95% CI 0.08–1.03, 2/
7061 subjects) [10]. However, this 6-month study included
only two urban hospitals [10]. To obtain more precise in-
cidences of invasive GBS in Guangdong province, we
retrospectively collected data of cases with culture-
confirmed invasive GBS disease among <3 months old in-
fants from three large urban tertiary hospitals for 2011–
2014. This study was to investigate the epidemiology of
GBS infections in south China and to provide evidence for
developing preventive interventions and the introduction
of GBS vaccines in the future.
Methods
Study design
This retrospective study was conducted within three
large urban tertiary hospitals in Guangdong (Guangzhou
Women & Children’s Medical Center, Guangdong Pro-
vincial Maternity & Children’s Hospital, and Zhongshan
Boai Hospital) from Jan 2011 to Dec 2014. Skilled atten-
dants in these hospitals provide maternity services to
pregnancies, intensive care units in these hospitals also
provide neonatal and pediatric medical services. This
study was approved by the local ethical committees of
three study hospitals.
Data collection
GBS cases were identified from the microbiology labora-
tory databases of the studying hospitals. All of the study
hospitals used automated enrichment culture methods to
identify GBS. A GBS case was defined as a < 3 months old
infant with a confirmed positive GBS culture from a sterile
sample accompanied any of clinical signs or symptoms of
sepsis, meningitis or pneumonia. EOD was defined as iso-
lation of GBS from the infants within the first 6 days after
birth, and late-onset disease (LOD) was defined as isola-
tion of GBS from the infants 7–89 days after birth. Only
culture-confirmed GBS cases born in the studying hospi-
tals were included for the estimation of incidence and
evaluation of clinical outcomes at discharge e.g. survived,
survived with sequelae and died. The medical records of
GBS cases were reviewed and extracted. The numbers of
live births per year between 2011 and 2014 were provided
by the statistical departments of studying hospitals.
GBS strain analysis
For suspected cases, blood and/or cerebrospinal fluid
(CSF) samples were taken into culture bottles and sent
to laboratories according to operation manuals of blood
culture system (BD Bactec™ 9210 or BioMerieux Bact/
ALERT). The Streptococcus genus was identified using
Gram stain, colony morphology, haemolysis, and a cata-
lase test. API 20STREP, an automated identification
panel for Gram-positive bacteria, was then employed
(VITEK 2 COMPACT, BioMerieux, France). GBS isolates
from culture-confirmed cases born elsewhere but trans-
ferred to the studying hospitals for medical treatment after
delivery also were enrolled into strain analysis. Antimicro-
bial susceptibility to penicillin, ceftriaxone, vancomycin,
linezolid, ofloxacin, sulfamethoxazole, tetracycline,
erythromycin, clindamycin, was examined using the
AST-GP67 (VITEK 2 COMPACT) or manual Kirby-Bauer
disc diffusion, as per interpretive standards established by
the Clinical and Laboratory Standards Institute (US) [11].
GBS isolates were recovered in trypticase soy agar supple-
mented with 5% sheep blood. Lancefield serotyping was
performed using a Strep-B-Latex® rapid latex agglutination
test kit (Statens Serum Institute, Hillerød, Denmark) ac-
cording to the manufacturer’s instructions. Multi-locus se-
quence typing (MLST) was performed by sequencing the
internal fragments of seven house-keeping genes (adhP,
pheS, atr, glnA, sdhA, glcK and tkt). PCR products were
purified and sequenced in both directions by BGI Tech
Solutions Co.,Ltd.. Alleles and sequence types (STs) were
determined using the S. agalactiae MLST website (http://
pubmlst.org/sagalactiae/).
Statistical analysis
The incidence per 1000 live births was calculated by div-
iding the total number of confirmed GBS cases born in
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the studying hospitals by the total number of infants
born in the studying hospitals and multiplying by 1000.
For both the incidence and mortality, 95% confidence in-
tervals (CI) were calculated using the Wilson interval
method. The percentage changes were used to compare
the incidences in each calendar year during the period of
this study. The mortality rate was defined as the per-
centage (%) of the GBS cases born in studying hospitals,
in which the infants died before discharge. The collected
strains isolated from GBS cases born in the studying
hospitals or elsewhere were enrolled for further analyses
of serotyping, MLST and antimicrobial susceptibility.
Serotype distribution is described as a frequency distri-
bution (number and percentage). All analyses were com-
pleted with SPSS 19.0 (IBM Corp., Armonk, NY, US),
and P < 0.05 was considered statistically significant.
Results
Incidence
Of the 127,206 live births in the three studying hospitals
between 2011 and 2014, 70 GBS cases were identified,
49 (70.0%) were EOD, and 21 (30.0%) were LOD
(Table 1). Among 70 GBS cases, 11 (15.7%) were born
less than 37 weeks gestational age and 9 (12.9%) weighed
less than 2500 g at delivery. The rates of preterm or low
birth weight in the EOD cases didn’t differ from that of
the LOD (P > 0.05). Of the total 70 cases, 5 (4 EOD and
1 LOD) died before discharge, for a mortality rate of
7.1% (95% CI 1.1–13.2), and 5 (7.1%, 2 EOD and 3 LOD)
had neurological sequelae (Fig. 1, Table 1).
The overall incidence of invasive GBS infection was
0.55 per 1000 live births (95% CI 0.44–0.69) during
2011–2014. The disease incidences increased signifi-
cantly from 0.29 per 1000 live births (95% CI 0.14–0.59)
in 2011 to 0.69 per 1000 live births (95% CI 0.48–1.01)
in 2014 (P < 0.05) (Fig. 2). Incidences for EOD and LOD
were 0.39 per 1000 live births (95% CI 0.29–0.51) and
0.17 per 1000 live births (95% CI 0.11–0.25), respect-
ively. The incidences of EOD in 2011, 2012, 2013, and
2014 were 0.12, 0.27, 0.48, and 0.58 per 1000 live births,
respectively (Fig. 2). The increase for EOD from 2011 to
2014 was significant (χ2 for trend, 10.158; P = 0.017).
While the incidence of LOD was more stable and ranged
from 0.11 to 0.24 per 1000 live births during the study-
ing period.
Distribution of serotypes and MLSTs
Within the retrospective study time, a total of 68 isolates
had been collected and stored from GBS infected cases
from infants who were born in the studying hospitals or
elsewhere but transferred to the studying hospitals for
medical treatment after delivery. To further characterise
the spectrum of GBS disease, the 68 GBS isolates were
enrolled for strain analyses (Table 2). Four serotypes
were identified, and all of the isolates were determined.
Serotype III (53, 77.9%) was the most commonly identi-
fied serotype among the GBS isolates, followed by Ib
(10, 14.7%), V (3, 4.4%), and Ia (2, 2.9%). Serotype III
was present in 68.2% of the 22 EOD cases and 82.6% of
the 46 LOD cases (χ2 = 0.303, P > 0.05, Fig. 3). MLST
analysis revealed the presence of 13 different STs among
the 68 GBS isolates (Table 3). The most frequent type
was ST-17(43, 63.2%), followed by ST-12(5, 17.6%), ST-
19(4, 5.9%), ST-23(3, 4.4%) and ST-1(3, 4.4%). All the
ST-17 were identified in serotype III isolates, which
accounted for 81.1% of ST of serotype III.
Antibiotic susceptibility
In prevention of perinatal group B streptococcal disease,
penicillin, ampicillin and cefazolin are recommended for
IAP or management of newborns with respect to risk for
early-onset GBS disease; second-line drugs such as
Table 1 Demographics of infants with invasive GBS infection in urban area of South China, 2011–2014
Early-onset Disease (n = 49) Late-onset Disease (n = 21) Total (n = 70)
Sex (female/male) 16/33 12/9 28/42
Preterm (gestational age < 37 weeks) 7 (14.3%) 4 (19.0%) 11 (15.7%)
Low birth weight (<2500 g) 5 (10.2%) 4 (19.0%) 9 (12.9%)
Bacterial isolation site
Blood alone 46 (93.9%) 16 (76.2%) 62 (88.6%)
CSF+blooda 2 (4.1%) 0 2 (2.9%)
CSF alone 1 (2.0%) 5 (23.8%)b 6 (8.6%)
Incidence (per 1000 live births,95%CI) 0.39 (0.29–0.51) 0.16 (0.11–0.25) 0.55 (0.44–0.69)
Clinical outcomes
Died 4 (8.2%) 1 (4.8%) 5 (7.1%)
Survived with sequelae 2 (4.1%) 3 (14.3%) 5 (7.1%)
aCSF cerebrospinal fluid;
bCompared with early-onset disease, Fisher exact test, X2 = 6.3281, P = 0.0119
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vancomycin, macrolides (i.e., erythromycin, azithromy-
cin, and clarithromycin), and lincosamides (clindamycin
and lincomycin) may be used as alternative in a patient
allergic to penicillin or cephalosporins. Penicillin G is
the drug of choice for treatment of GBS infections. As
shown in Table 4, all the 68 GBS isolates were suscep-
tible to penicillin, ceftriaxone, vancomycin, and linezolid.
There were 4 (5.9%) and 2 (2.9%) isolates were resistant
to ofloxacin and sulfamethoxazole, respectively. The
rates of resistance to erythromycin and clindamycin
were 57.4% (39/68) and 51.5% (35/68), respectively. The
isolates showed a high resistance (65/68, 95.6%) to tetracyc-
line. 33.8% (23/68) isolates showed multi-drug resistance to
tetracycline, lincosamides and macrolides. However, dif-
ference in resistance to erythromycin and clindamycin
couldn’t be observed between serotype III or ST-17 GBS
isolates with the rest other types.
Discussion
GBS is an important cause of neonatal sepsis and men-
ingitis. Considerable demographic variation exists in
terms of incidence and other disease burden indicators
[5, 6]. The overall incidence of invasive neonatal GBS
disease (0.55 per 1000 live births, 95% CI 0.44–0.69) in
Guangdong between 2011 and 2014, was close to the
global average estimation (0.53 per 1000 live births, 95%
CI 0.44–0.62) [5]. However the incidence rate in this
study is much higher than which was suggested in our
previous short-term observation [10] and in other Asian
countries with the incidences rate 0.14–0.41 per 1000
live births [12, 13]. Furthermore, GBS in EOD increased
markedly from 2011 to 2014, reaching 0.58 per 1000 live
births. The overall incidence of EOD (0.39 per 1000 live
births, 95% CI 0.29–0.51) was higher than that from
studies with any IAP (0.23 per 1000 live births) and
lower than that from studies with no IAP (0.75 per 1000
live births) [5]. IAP was not implemented in these three
hospitals during the study period. Hence, the possible
reason about the incidence of LOD was more stable than
EOD include: Firstly, some LOD cases might go to other
hospitals rather than the studying hospitals if they
moved elsewhere; doctors paid more attention to the
GBS identification over time so that the blood/CSF sam-
ples could be taken more timely than before. Secondly,
the clinical symptoms of LOD mostly present as neuro-
logical sequelae. Therefore, the blood and cerebrospinal
fluid from patients with similar symptoms are routinely
examined for the presence of bacteria in these samples.
However, the symptoms of EOD are similar to respiratory
infections which may be treated with broad-spectrum
Fig. 1 Clinical outcomes of culture-confirmed GBS cases identified
from infants <3 months born in the three studying hospitals. This
figure indicates number of GBS cases was identified from 127,206
live births, mortality rate of EOD and LOD, and proportion of cases
with neurological sequelae, respectively. EOD, early-onset disease;
LOD, late-onset disease
Fig. 2 Incidence of invasive group B streptococcal disease in infants younger than three months in South China, 2011–2014. This figure describes
the overall incidence of invasive GBS infection during 2011–2014, and incidence for EOD and LOD, respectively. It shows the increase for EOD
from 2011 to 2014 was significant, while the incidence of LOD was more stable
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antibiotics before blood culture examination. After intro-
ducing the tighten regulations of antibiotic usage gradually
in the study hospitals since 2012, more blood samples
from potential bacteria-infected patients were examined
and more GBS infection from EOD patients were identi-
fied. This may reflect the realistic situation of GBS infec-
tions especially in EOD incidences. The growing number
of sterile samples were sent to the laboratory for bacterial
examination using the same experimental facilities under
the same examining standard in study hospitals over the
studying period [14]. The increasing GBS infection rate
was identified and suggested that GBS is an important
pathogen of invasive neonatal infections and increases the
threat to neonatal health in Guangdong in south China.
In this study the proportion of EOD (70%) is higher
than that of LOD (30%). In other Asian countries such
as Japan and Korea, reported that the LOD account for
75% (45/60) and 80% (125/157), respectively [13, 15]. An
important risk factor for EOD is GBS colonization of
maternal vaginal and rectal sites during late pregnancy.
No data about GBS colonization in Guangdong has been
reported. A study conducted in the other Chinese city,
Beijing, showed that 7.1% of pregnant women had GBS
present in the vaginal-rectal tract [16] which is lower
than some developed countries (15–25%) [17, 18]. Fur-
ther study to explore the relationship between EOD and
maternal GBS recto-vaginal colonization will be neces-
sary in Guangdong in the future.
The overall mortality in the present study was 7.1%
(95% CI 1.1–13.2%), which is lower than the global aver-
age with 9.6% (95% CI 7.5–11.8) [5], 13.6% for EOD and
8.0% for LOD in Japan [19], 6.2% in India [20] and
20.7% for EOD and 7.2% for LOD in Korea [15]. The ad-
ministration of broad spectrum antibiotics and neonatal
senior nursing interventions that were provided to sus-
pected cases of sepsis may reduce the mortality rate in
the studying hospitals. In addition, the relatively low
mortality might be relevant with most of cases with a
normal birth weight. The proportion of LOD cases with
neurological sequelae was lower than the reported 25%–
35% in other countries [19, 21].
The studying hospitals provided effective anti-infection
treatment for GBS cases in a timely manner and rehabili-
tation for cases with neurological signs, which are import-
ant to reduce the case fatality ratio and sequelae. In this
study, the clinical isolated GBS strains are all susceptible
to beta-lactam antibiotics including penicillin, ampicillin
and cefazolin. Thus beta-lactam antibiotics are ideal to
treat GBS diseases in the studying area. For the infants
who are allergic to penicillin, considering high resistant
rate to erythromycin and clindamycin (57.4% and 51.5%,
respectively) in this study and the reported global increase
in resistance to erythromycin and clindamycin over the
last two decades [22, 23], other antibiotics should be
chosen. Furthermore, 95.6% of isolates resistant to tetra-
cycline and 33.8% of isolates showed multi-drug resistance
Table 2 Serotyping analysis of invasive GBS infection in urban
area of South China, 2011–2014
Early-onset Disease
(n = 22)
Late-onset Disease
(n = 46)
Totala
(n = 68)
Sex (female/male) 6/16 25/21 31/37
Bacterial isolation site
Blood 20 (90.9%) 28 (60.9%) 48 (70.6%)
CSFb 2 (9.1%) 18 (39.1%) 20 (29.4%)
Serotypec
Ia 1 (4.5%) 1 (2.2%) 2 (2.9%)
Ib 5 (22.7) 5 (10.9%) 10 (14.7%)
III 15 (68.2%) 38 (82.6%) 53 (77.9%)
V 1 (4.5%) 2 (4.3%) 3 (4.4%)
aThe analyzed 68 GBS isolates were collected during study period, including
from cases born in the studying hospitals or born elsewhere but transferred to
the studying hospitals for medical treatment after delivery
bCSF cerebrospinal fluid
cCompared with early-onset disease, serotypes distribution for late-onset disease
was not statistically different (X2 = 2.1062, P = 0.5506)
(a) (b)
Fig. 3 Distribution of group B streptococcus serotypes in infants younger than three months with invasive infection. This figure shows GBS
serotype distribution among study infants. Serotype III was the most commonly identified serotype, followed by Ib, V, and Ia
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to lincosamides and macrolides. The antibiotics resistance
had no correlation to any particular serotypes or MLSTs
which suggested the ability of antibiotic-resistance in clin-
ical GBS strains is universal and there is no barrier of
antibiotic-resistance spreading between different serotypes
or MLSTs. It is necessary to unremittingly observe the
antibiotic resistance of GBS in Guangdong and a guideline
for reasonable usage of antibiotics against GBS is desired.
Knowledge of the serotype is crucial to the development
of serotype-based vaccines against GBS disease. Serotype
distribution varies by country and region [24, 25], with
serotype III predominating worldwide [5, 10, 26, 27]. It is
well comparable to the results of our study. In this study,
the percentage of serotype III was 77.9%, among these,
81.1% were caused by ST-17, which is higher than the
similar study in Japan that half (50.0%) of the serotype III
strains were ST17 [28]. The use of potential GBS vaccines
during pregnancy will not only overcome problems caused
by IAP (e.g., no impact on LOD and antibiotic resistance),
reducing the incidence and mortality of GBS disease
[17, 29]. The trivalent GBS vaccine covering serotypes
Ia, Ib, and III was also well tolerated and induced
capsular-specific antibody responses [30], which are as-
sociated with 95.6% of GBS cases in the present study,
92.7% of GBS cases in Japan [28] and approximately
79% of GBS cases globally [5]. Furthermore, the sero-
typing in the present study indicated that a pentavalent
conjugate vaccine covering serotypes Ia, Ib, II, III, and
V could potentially prevent 100% of neonatal invasive
GBS disease; these five capsular serotypes corresponded
to 95% of invasive disease worldwide [5]. The findings
were also consistent with a recent study among preg-
nant women in Beijing, which reported that serotypes
III, Ia, V, and Ib accounted for 91.3% of all serotyped
isolates [16].
All false-negative cases, spontaneous abortions and
stillbirths caused by GBS infection might have been
missed and not been included in this study. Further-
more, this study was conducted in three urban hospitals
which are regarded as the best institutions for infant dis-
ease treatment in South China, it is difficult to monitor
the outcomes and infections incidences after patients
discharged from occasional visits. The prolonged study-
ing period and expanded studying area will overcome
the limitation of this study. Acquiring the duration and
dosage of intrapartum antibiotics usage for GBS-
colonized pregnant women in the course of delivery is
necessary to include in the future study.
Conclusions
This study is the first long-term epidemiology study on
neonatal GBS infection in south China. Increasing GBS
diseases cases and antibiotics resistance is notable in the
three studying urban hospitals and serotype III and ST-
17 are dominated in the GBS infection in the studying
Table 3 Multi-locus sequence typing of invasive GBS infection
in urban area of South China, 2011–2014
Serotype Total No Sequence Type Isolates number
III 53 ST-17 43
ST-19 4
ST-399 2
ST-27 1
ST-55 1
ST-562 1
ST-651 1
Ib 10 ST-12 5
ST-10 1
ST-23 1
ST-357 2
ST-579 1
V 3 ST-1 3
Ia 2 ST-23 2
Table 4 Antibiotic resistance of invasive GBS isolates in different serotypes and STs
Serotypes Sequence types
Ia (n = 2) Ib (n = 10) III (n = 53) V (n = 3) Total (n = 68) ST-17 (n = 43) Non-ST-17 (n = 25)
Penicillin 0 0 0 0 0 0 0
Ceftriaxone 0 0 0 0 0 0 0
Vancomycin 0 0 0 0 0 0 0
Linezolid 0 0 0 0 0 0 0
Ofloxacin 0 1 (10.0%) 3 (5.7%) 0 4 (5.9%) 0 4 (16.0%)a
Sulfamethoxazole 0 1 (10.0%) 1 (1.9%) 0 2(2.9%) 1 (2.3%) 1 (4.0%)
Tetracycline 2 (100.0%) 9 (90.0%) 51 (96.2%) 3 (100.0%) 65 (95.6%) 42 (97.7%) 23 (92.0%)
Erythromycin 1 (50%) 5 (50%) 31 (58.5%) 2 (66.7%) 39(57.4%) 26 (60.5%) 11 (44.0%)
Clindamycin 0 5 (50%) 28 (52.8%) 2 (66.7%) 35(51.5%) 25 (58.1%) 9 (36.0%)
aCompared to ST-17 isolates, X2 = 4.706, P = 0.030, 3/4(75.0%) ST-19 were resistant to ofloxacin
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period. Our data provide the window to observe the
trend of GBS infections in this area and will facilitate the
development of the guidance for reasonable antibiotics
usage and for the GBS vaccines in the future.
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